华润医药2023年年报

CONTENTS 02Corporate Profile03Corporate Information07Definitions12Chairman’s Statement16Highlights of the Year22Awards30Financial Highlights31Management Discussion and Analysis65Corporate Governance Report89Biographies–Directors and Senior Management102Report of the Directors127Independent Auditor’s Report135Consolidated Statement of Profit or Loss136Consolidated Statement of Comprehensive Income137Consolidated Statement of Financial Position139Consolidated Statement of Changes in Equity141Consolidated Statement of Cash Flows144Notes to Consolidated Financial Statements 公司簡介Corporate Profile 華潤醫藥集團有限公司（股份代號：3320）是中國領先的綜合醫藥公司，業務範疇覆蓋醫藥及保 健 產 品 的 生 產、分 銷 及 零 售。本 集 團 成 立 於二零零七年，現已發展成中國前五大醫藥製造商兼中國前三大醫藥產品分銷商（按收益）。 China Resources Pharmaceutical Group Limited (stock code: 3320) is a leadingintegrated pharmaceutical company in China. Our business encompassesmanufacturing, distribution and retail of pharmaceutical and healthcareproducts. Since the establishment in 2007, the Group has developed into oneof the fifth largest pharmaceutical manufacturers and one of the third largestpharmaceutical distributors (by revenue) in China. 本公司於二零一六年十月在香港成功完成全球發 售。我 們 的 製 造 業 務 涵 蓋 研 發、生 產 及 銷 售醫藥產品。我們生產796種藥品，產品組合包括化學藥品、中藥、生物藥以及營養保健品，覆蓋廣 泛 治 療 領 域，包 括 心 血 管、消 化 道 和 新 陳 代謝、大容量靜脈注射液、兒科、呼吸系統、皮膚等。此 外，我 們 擁 有「999」、「東 阿 阿 膠」、「雙鶴」、「紫竹」、「江中」、「博雅」及「昆藥集團」等多個馳名品牌，業務覆蓋感冒、胃腸、皮膚、兒科、骨科、血製品等品類，未來將積極向健康管理、慢病管理產品延伸，滿足中國家庭從預防、保健、治療、康復，全週期、多層次的健康需求。 In October 2016, the Company successfully completed its global offering inHong Kong. Our manufacturing business encompasses the research anddevelopment, manufacturing and sale of pharmaceutical products. Wemanufacture 796 products comprising chemical drugs, Chinese medicines andbiological drugs as well as nutritional and healthcare products, covering awide range of therapeutic areas including cardiovascular, alimentary tract andmetabolism, large-volume IV infusion, pediatrics, respiratory system,dermatology, etc. Moreover, we own a range of famous brands, such as“999”,“Dong-E-E-Jiao”,“Double Crane”,“Zizhu”,“Jiangzhong”,“Boya”and“KPC”, covering therapeutic areas including cold, gastroenterology,dermatology, pediatrics, orthopedics, plasma products, among others. Infuture, we will actively expand into health management and products forchronic disease management to meet the full-cycle and multi-dimensionalhealthcare needs of Chinese households from prevention, healthcare, therapyto recovery. 我們視研發創新為長期發展的重要驅動力，持續 加 大 研 發 投 入，具 有 一 個 國 家 重 點 實 驗 室、五個國家工程技術研究中心、一個國家產業創新中心、三個國家級企業技術中心，以及70餘個獲省市級研發平台，研發人員超過2,700名。 We regard R&D and product innovation as important drivers for our long-termgrowth and consistently increase the investment in R&D activities. We operateone national key laboratory, five national engineering technology researchcenters, one national industrial innovation center, three national enterprisetechnology centers and over 70 provincial R&D platforms, with a R&D teamcomprising over 2,700 staff members. 憑藉我們全面的產品供應及廣泛的分銷網路，我們向中國的醫院及其他醫療機構直接分銷產品。我們經營著一個由超過230個物流中心構成的全國性分銷網路，戰略性覆蓋中國28個省、直轄市及自治區，客戶數量約24萬家，其中包括 二、三 級 醫 院10,667家，基 層 醫 療 機 構 客 戶約 十 萬 家。另 外，我 們 經 營 中 國 最 大 零 售 藥 房網路之一，我們以「華潤堂」和「德信行」等全國或地區性的優質品牌來經營790家零售藥房，其中 包 括DTP專 業 藥 房272家（含「雙 通 道」藥 店153家）。 Leveraging our comprehensive product supply and wide distribution networks,we directly distribute products to hospitals and other medical institutionsacross the country. We operate a national distribution network comprisingover 230 logistics centers strategically across 28 provinces, municipalities andautonomous regions in China, with around 240,000 clients, including 10,667second- and third-class hospitals and approximately 100,000 primary medicalinstitution clients. In addition, we operate one of the largest retail pharmacynetworks in China, comprising 790 retail pharmacies under national orregional premium brands—“CR Care（華潤堂）”and“Teck Soon Hong（德信 行）”, including 272 DTP specialty pharmacies (which cover 153“dualchannel（雙通道）”pharmacies). 公司資料Corporate Information 韓躍偉先生 BOARD OF DIRECTORS Chairman and non-executive DirectorMr. Han Yuewei 白曉松先生 Executive Director and Chief Executive OfficerMr. Bai Xiaosong 陶然先生 Executive Director and Vice PresidentMr. Tao Ran Executive Director and Chief Financial OfficerMdm. Deng Rong(appointed Chief Financial Officer on 13 June 2023)(appointed Executive Director on 27 December 2023) 鄧蓉女士（於二零二三年六月十三日獲委任首席財務官）（於二零二三年十二月二十七日獲委任執行董事） Executive Director, Chief Financial Officer and Vice PresidentMdm. Weng Jingwen(resigned on 13 June 2023) 翁菁雯女士（於二零二三年六月十三日辭任） Non-executive Directors Mdm. Guo Wei(appointed on 13 February 2023)Mr. Sun Yongqiang(appointed on 27 December 2023)Mr. Hou BoMdm. Jiao RuifangMr. Lin Guolong(resigned on 27 December 2023) 郭巍女士（於二零二三年二月十三日獲委任）孫永強先生（於二零二三年十二月二十七日獲委任）侯博先生焦瑞芳女士林國龍先生（於二零二三年十二月二十七日辭任） Independent non-executive Directors Mdm. Shing Mo Han YvonneMr. Kwok Kin FunMr. Fu TingmeiMr. Zhang Kejian 盛慕嫻女士郭鍵勳先生傅廷美先生張克堅先生 公司資料Corporate Information AUDIT COMMITTEE